PI Industries Ltd (NSE:PIIND)

Q3 2025 PI Industries Ltd Earnings Call Transcript

Feb 07, 2025 / 10:30AM GMT

Release Date Price: ₹3543.85 (-2.68%)

Transcript

Key Points

Positve

PI Industries Ltd (BOM:523642) reported a significant revenue growth of 72% year-over-year for Q3 FY25, reaching INR19,008 million.
The company has seen a strong performance in new product growth, with a 40% year-on-year increase in the agchem export segment.
PI Industries Ltd (BOM:523642) has maintained a healthy net cash balance of INR42,091 million, indicating strong financial health.
The company is expanding its portfolio with six new domestic brands introduced this year and a pipeline of 20-plus products under evaluation.
PI Industries Ltd (BOM:523642) is focusing on sustainability, being ranked in the top 3% of ESG-related companies and listed in the S&P Sustainability Yearbook for 2024 and 2025.

Negative

The global crop protection industry is experiencing a transition downturn, affecting market dynamics.
Domestically, the generic segment is facing ongoing pricing pressure and elevated inventory levels.
The company's effective tax rate (ETR) increased from 14.7% to 22.5%, impacting net profit for the quarter.
The biologicals business, despite showing growth, is currently at a low base and requires significant investment to scale.
PI Industries Ltd (BOM:523642) is facing challenges in the agchem sector due to geopolitical scenarios and fluctuating input costs.

Operator

Ladies and gentlemen, the conference of PI Industries will begin shortly. Please stay connected. Thank you.

Ladies and gentlemen, good day, and welcome to the PI Industries Q3 FY25 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Nishid Solanki from CDR India. Thank you, and over to you, sir.

Nishid Solanki

CDR India - Investor Relations

Thank you. Good afternoon, everyone, and thank you for joining us on PI Industries Q3 FY25 earnings conference call. Today, we are joined by senior members of the management team, including Mr. Mayank Singhal, Executive Vice Chairman and Managing Director; Mr. Rajnish Sarna, Joint Managing Director; Mr. Sanjay Agarwal, Group Chief Financial Officer; Dr. Atul Gupta, CEO Exports; Mr. Prashant Hegde, CEO Domestic; and Dr. Ramesh Subramanian, Global CEO, PI Health Sciences.

We will begin the call with key perspective from Mr. Singhal. After that, we will have Mr. Agarwal sharing his views on the company's financial

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.